Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19100372 | CRYSTAL FORM OF SPIROCYCLIC AMINE ARYL PHOSPHORUS OXIDE COMPOUND AND PREPARATION METHOD THEREFOR | June 2025 | March 2026 | Allow | 13 | 2 | 0 | No | No |
| 19094187 | HETEROCYCLIC GLP-1R AGONISTS | March 2025 | December 2025 | Allow | 8 | 1 | 1 | No | No |
| 19020628 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | January 2025 | June 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18999662 | EPINEPHRINE COMPOSITIONS AND CONTAINERS | December 2024 | May 2025 | Allow | 4 | 1 | 0 | No | No |
| 18941137 | PHARMACEUTICAL COMPOSITIONS COMPRISING NILOTINIB | November 2024 | June 2025 | Allow | 7 | 2 | 0 | Yes | No |
| 18775916 | CRYSTALLINE FORMS OF (S, E)-4-(DIMETHYLAMINO)-N-(3-(4-(2-HYDROXY-1-PHENYLETHYLAMINO)-6-PHENYLFURO[2,3-D]PYRIMIDIN-5-YL)PHENYL)BUT-2-ENAMIDE FREE BASE | July 2024 | October 2024 | Abandon | 3 | 1 | 0 | No | No |
| 18659374 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | May 2024 | September 2025 | Allow | 16 | 1 | 0 | No | No |
| 18633460 | COMPOUNDS AS MYT1 INHIBITORS | April 2024 | August 2024 | Allow | 4 | 1 | 0 | Yes | No |
| 18612067 | Self-Emulsifying Systems For Cannabinoids | March 2024 | September 2025 | Allow | 18 | 3 | 0 | No | No |
| 18612156 | IRAK4 Inhibitors | March 2024 | July 2024 | Allow | 4 | 0 | 0 | No | No |
| 18601926 | METHODS OF USING DMT | March 2024 | June 2025 | Allow | 15 | 2 | 0 | Yes | No |
| 18589930 | Process for Manufacturing Pibrentasvir Active Drug Substance | February 2024 | September 2025 | Allow | 18 | 0 | 0 | No | No |
| 18437931 | EPINEPHRINE COMPOSITIONS AND CONTAINERS | February 2024 | April 2025 | Allow | 14 | 2 | 0 | Yes | Yes |
| 18290244 | SLOW-RELEASE FORMULATION | November 2023 | September 2025 | Allow | 22 | 3 | 0 | Yes | No |
| 18495374 | Polysorbate Mixtures Having Modified Fatty Acid Ester Distribution | October 2023 | March 2026 | Allow | 29 | 1 | 0 | No | No |
| 18491057 | CRYSTALLINE FORMS OF TROFINETIDE | October 2023 | August 2025 | Allow | 22 | 1 | 0 | No | No |
| 18375720 | PREVENTION AND/OR TREATMENT OF CNS DISORDERS | October 2023 | August 2025 | Abandon | 22 | 1 | 0 | No | No |
| 18469132 | 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS | September 2023 | September 2025 | Abandon | 24 | 1 | 0 | No | No |
| 18368208 | METHODS OF TREATING HEART FAILURE WITH PRESERVED EJECTION FRACTION USING MODIFIED FORMS OF TRIMETAZIDINE | September 2023 | August 2025 | Allow | 23 | 1 | 0 | No | No |
| 18230329 | Substituted Piperidino Compounds and Related Methods of Treatment | August 2023 | July 2025 | Allow | 23 | 1 | 0 | No | No |
| 18077431 | DOSING REGIMENS OF (S)-1-(4-FLUOROPHENYL)-1-(2-(4-(6-(1-METHYL-1H-PYRAZOL-4-YL)PYRROLO[2,1-F][1,2,4]TRIAZIN-4-YL)PIPERAZIN-1-YL)PYRIMIDIN-5-YL)ETHAN-1-AMINE FOR TREATMENT OF INDOLENT SYSTEMIC MASTOCYTOSIS | December 2022 | November 2024 | Allow | 23 | 2 | 0 | Yes | No |
| 18073782 | BICYCLIC AMINE CDK12 INHIBITORS | December 2022 | January 2026 | Allow | 37 | 2 | 1 | Yes | No |
| 18060864 | 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS | December 2022 | April 2023 | Allow | 4 | 1 | 0 | No | No |
| 17972633 | Polyherbal Self Micro-Emulsifying Delivery System (SMEDS) composition for multi-disease treatment | October 2022 | November 2024 | Allow | 25 | 1 | 0 | Yes | No |
| 17822438 | SUBSTITUTED AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS | August 2022 | December 2023 | Allow | 16 | 1 | 0 | No | No |
| 17819157 | MULTI-TARGETED TYROSINE KINASE INHIBITORS EFFECTIVE IN ANTITUMOR USES | August 2022 | April 2024 | Allow | 20 | 2 | 0 | No | No |
| 17885493 | COVALENT INHIBITORS OF MENIN-MLL INTERACTION FOR DIABETES MELLITUS | August 2022 | January 2025 | Allow | 29 | 2 | 0 | No | No |
| 17815400 | PROCESSES FOR PREPARING TUCATINIB POLYMORPHS | July 2022 | February 2024 | Abandon | 19 | 0 | 1 | No | No |
| 17862865 | CRYSTALLINE FORMS OF TROFINETIDE | July 2022 | July 2023 | Allow | 12 | 0 | 0 | No | No |
| 17788393 | NOVEL AMIDE DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOF | June 2022 | February 2026 | Allow | 44 | 1 | 0 | No | No |
| 17842372 | STABLE TRYPTAMINE ORAL FILMS | June 2022 | June 2025 | Allow | 36 | 3 | 0 | No | No |
| 17836089 | Process for Producing A Vegan Cannabinoid Chewy | June 2022 | February 2024 | Allow | 21 | 1 | 0 | No | No |
| 17835480 | SOLID FORMS OF PONATINIB HYDROCHLORIDE AND PROCESS THEREOF | June 2022 | March 2024 | Abandon | 21 | 0 | 1 | No | No |
| 17833113 | METHOD FOR PREPARING NICOTINAMIDE MONONUCLEOTIDE COCRYSTAL | June 2022 | January 2024 | Allow | 19 | 0 | 0 | No | No |
| 17829933 | 3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses thereof | June 2022 | December 2023 | Allow | 19 | 1 | 0 | No | No |
| 17780235 | COMPOUNDS FOR TREATING TUBERCULOSIS | May 2022 | September 2025 | Allow | 40 | 1 | 0 | No | No |
| 17779418 | COMPOSITION AND METHOD FOR CONVERTING HUMAN GILIAL CELLS INTO NEURONS | May 2022 | February 2026 | Abandon | 45 | 1 | 0 | No | No |
| 17663760 | METHODS FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS WITH MUSCARINIC RECEPTOR ACTIVATION AND ANTIPSYCHOTICS | May 2022 | January 2024 | Abandon | 20 | 1 | 0 | No | No |
| 17732018 | DESIGN AND SYNTHESIS OF DUAL 5-HT1A AND 5-HT7 RECEPTOR LIGANDS | April 2022 | January 2024 | Allow | 21 | 2 | 0 | No | No |
| 17730395 | HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING | April 2022 | March 2023 | Allow | 10 | 0 | 0 | No | No |
| 17726971 | STABILIZED FORMULATIONS | April 2022 | February 2026 | Allow | 46 | 1 | 0 | No | No |
| 17727532 | CANNABINOID EMULSION COMPOSITION AND METHOD OF MANUFACTURING | April 2022 | July 2024 | Abandon | 27 | 1 | 0 | No | No |
| 17723758 | GLP-1R MODULATING COMPOUNDS | April 2022 | January 2024 | Allow | 21 | 1 | 1 | No | No |
| 17713455 | Combination Therapies Using PRMT5 Inhibitors for the Treatment of Cancer | April 2022 | August 2024 | Allow | 28 | 2 | 1 | No | No |
| 17708072 | 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS | March 2022 | June 2023 | Allow | 14 | 0 | 0 | No | No |
| 17704789 | Use of ZT-1A and Analogs Thereof to Prevent and/or Treat Neurodegenerative and Neurocognitive Disorders | March 2022 | January 2024 | Allow | 21 | 2 | 0 | No | No |
| 17763037 | PEDIATRIC TRAZODONE COMPOSITIONS AND METHOD OF TREATMENT THEREOF | March 2022 | October 2025 | Allow | 42 | 1 | 0 | No | No |
| 17699082 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | March 2022 | December 2023 | Allow | 21 | 1 | 1 | No | No |
| 17698956 | COMPOUNDS HAVING ((3-NITROPHENYL)SULFONYL)ACETAMIDE AS BCL-2 INHIBITORS | March 2022 | July 2023 | Allow | 16 | 2 | 0 | No | No |
| 17696279 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONIST FOR THE TREATMENT OF DISEASE | March 2022 | December 2024 | Allow | 33 | 1 | 0 | No | No |
| 17688369 | PTGR2 INHIBITORS AND THEIR USE | March 2022 | August 2023 | Allow | 17 | 1 | 0 | No | No |
| 17677698 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | February 2022 | October 2024 | Allow | 32 | 4 | 0 | Yes | No |
| 17631804 | METHOD FOR TREATING ALZHEIMER'S DISEASE BY INHIBITING UPTAKE OF AMINO ACIDS BY T CELLS | January 2022 | October 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17588173 | METHODS OF MAKING TRANS ISOMERIC FORMS OF G PROTEIN-COUPLED RECEPTOR MODULATORS | January 2022 | September 2024 | Allow | 32 | 2 | 1 | Yes | No |
| 17311536 | PYRROLO[2,3-D]PYRIMIDIN-2-ONE ANTIMICROBIAL COMPOUNDS | January 2022 | July 2025 | Allow | 50 | 1 | 0 | No | No |
| 17586751 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | January 2022 | November 2023 | Abandon | 21 | 0 | 1 | No | No |
| 17571105 | SYNERGISTIC NUTRITIONAL COMPOSITIONS FOR TREATING NEUROCOGNITIVE DISORDERS | January 2022 | January 2025 | Allow | 36 | 4 | 0 | No | No |
| 17560048 | METHODS OF PREPARING HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | December 2021 | August 2023 | Allow | 20 | 2 | 0 | No | No |
| 17556295 | SUBSTITUTED PIPERIDINO COMPOUNDS AND RELATED METHODS OF TREATMENT | December 2021 | May 2023 | Allow | 17 | 1 | 0 | No | No |
| 17548161 | METHODS OF TREATING PROSTATE CANCER | December 2021 | January 2024 | Abandon | 25 | 1 | 1 | No | No |
| 17540646 | METHODS OF TREATING HEART FAILURE WITH HIBERNATING MYOCARDIUM USING MODIFIED FORMS OF TRIMETAZIDINE | December 2021 | April 2024 | Allow | 29 | 3 | 0 | No | No |
| 17540653 | METHODS OF TREATING HEART FAILURE WITH PRESERVED EJECTION FRACTION USING MODIFIED FORMS OF TRIMETAZIDINE | December 2021 | June 2023 | Allow | 19 | 1 | 0 | No | No |
| 17528342 | PREVENTION AND/OR TREATMENT OF CNS DISORDERS | November 2021 | June 2023 | Allow | 19 | 1 | 0 | No | No |
| 17486123 | COMPOSITIONS COMPRISING CANNABINOIDS AND METHODS OF USE THEREOF | September 2021 | October 2023 | Abandon | 24 | 1 | 0 | No | No |
| 17483234 | POLYSORBATE MIXTURES HAVING MODIFIED FATTY ACID ESTER DISTRIBUTION | September 2021 | July 2023 | Allow | 22 | 1 | 0 | No | No |
| 17470243 | Method for Treating Pruritus | September 2021 | December 2024 | Allow | 39 | 3 | 0 | No | No |
| 17408956 | Inhibitors of SARM1 | August 2021 | October 2023 | Allow | 26 | 1 | 1 | Yes | No |
| 17445588 | COMPOUNDS AS GLP-1R AGONISTS | August 2021 | October 2023 | Abandon | 26 | 0 | 1 | No | No |
| 17429831 | PYRIDAZINIUM COMPOUNDS FOR USE IN A METHOD OF CONTROLLING UNWANTED PLANT GROWTH | August 2021 | May 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17427831 | 2-AMINOQUINAZOLINONE DERIVATIVE | August 2021 | April 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17373707 | BRANCHED AMINO ACID SURFACTANTS FOR USE IN HEALTHCARE PRODUCTS | July 2021 | August 2023 | Allow | 25 | 2 | 0 | No | No |
| 17419347 | Process for Preparation of Imidacloprid Polymorph Form I | June 2021 | November 2025 | Allow | 53 | 3 | 0 | No | No |
| 17354751 | METHODS OF TREATING PULMONARY DISEASES AND DISORDERS | June 2021 | May 2025 | Abandon | 46 | 1 | 0 | No | No |
| 17416222 | C-TERMINAL SRC KINASE INHIBITORS | June 2021 | May 2025 | Allow | 47 | 2 | 0 | No | No |
| 17347823 | ANTIMICROBIAL, ANTIVIRAL OR BIOCIDE COATING COMPOSITIONS | June 2021 | July 2023 | Allow | 25 | 0 | 1 | No | No |
| 17303845 | CRYSTALLINE ALK5 INHIBITORS AND USES THEREOF | June 2021 | December 2023 | Allow | 30 | 1 | 0 | No | No |
| 17297100 | TEAT DISINFECTANT COMPOSITION | May 2021 | October 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17296008 | PHARMACEUTICAL COMPOSITION COMPRISING HISTONE DEACETYLASE 6 INHIBITORS | May 2021 | October 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17295153 | AQUEOUS SOLUTIONS OF POORLY SOLUBLE PESTICIDES USING POLYALKYOXYLATED ALCOHOLS | May 2021 | March 2025 | Abandon | 46 | 2 | 0 | No | No |
| 17313977 | TREATMENTS FOR COVID-19-RELATED SYSTEMIC SCLEROSIS, VASCULAR INSUFFICIENCY, DISTAL ISCHEMIA, AND RELATED DISEASE CONDITIONS | May 2021 | August 2024 | Abandon | 39 | 2 | 1 | No | No |
| 17288258 | METHODS AND MATERIALS FOR TREATING NEUROPSYCHIATRIC DISORDERS | April 2021 | April 2025 | Abandon | 48 | 2 | 0 | No | No |
| 17287492 | WDR5 INHIBITORS AND MODULATORS | April 2021 | January 2024 | Allow | 33 | 0 | 0 | No | No |
| 17285918 | PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | April 2021 | December 2023 | Allow | 32 | 1 | 0 | No | No |
| 17285889 | PHARMACEUTICAL CRYSTAL OF CONTEZOLID ACEFOSAMIL, PREPARATION METHOD THEREFOR, AND USES THEREOF | April 2021 | June 2024 | Allow | 38 | 1 | 0 | Yes | No |
| 17285064 | Cyclic compounds as receptor modulating therapeutics and methods and uses thereof | April 2021 | January 2025 | Allow | 45 | 2 | 0 | Yes | No |
| 17226356 | H2O CRYSTAL FORMS OF A TCA CYCLE INTERMEDIATE CONJUGATE | April 2021 | August 2023 | Abandon | 28 | 0 | 1 | No | No |
| 17279705 | ANTI-NEURODEGENERATIVE COMBINATIONS AND USE FOR TREATMENT OF NEURODEGENERATIVE DISEASES | March 2021 | November 2025 | Allow | 55 | 2 | 0 | No | No |
| 17273510 | ARYL HYDROCARBON RECEPTOR ANTAGONISTS AND METHODS OF USE | March 2021 | April 2025 | Abandon | 49 | 1 | 1 | No | No |
| 17185750 | AZA-PYRIDONE COMPOUNDS AND USES THEREOF | February 2021 | June 2023 | Allow | 27 | 0 | 0 | No | No |
| 17268406 | INTEGRIN ANTAGONISTS | February 2021 | June 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17267885 | Process for Manufacturing Pibrentasvir Active Drug Substance | February 2021 | November 2023 | Allow | 33 | 0 | 0 | No | No |
| 17163010 | FIXED DOSE COMBINATION OF CHOLINESTERASE INHIBITOR AND A QUATERNARY AMMONIUM ANTIMUSCARINIC AGENT TO TREAT NEURODEGENERATIVE COGNITIVE DISORDERS | January 2021 | May 2024 | Allow | 40 | 2 | 1 | No | No |
| 17162670 | SMALL MOLECULE ENTEROVIRUS INHIBITORS AND USES THEREOF | January 2021 | January 2026 | Abandon | 60 | 6 | 0 | No | No |
| 17259451 | ARYL-N-ARYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | January 2021 | April 2024 | Allow | 39 | 2 | 0 | No | No |
| 17256330 | HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | December 2020 | March 2024 | Allow | 39 | 1 | 0 | No | No |
| 17126364 | COMPLEX, CONTRAST AGENT AND METHOD FOR TREATING A DISEASE RELATED TO CXCR4 RECEPTOR | December 2020 | January 2024 | Allow | 37 | 1 | 0 | No | No |
| 17051016 | OPHTHALMIC COMPOSITIONS COMPRISING TAFLUPROST FOR THE TREATMENT OF GLAUCOMA | October 2020 | August 2024 | Allow | 46 | 2 | 0 | No | No |
| 17047961 | QUINOLINE DERIVATIVES AS INHIBITORS OF AXL/MER RTK AND CSF1R | October 2020 | July 2024 | Allow | 45 | 2 | 1 | No | No |
| 17045150 | ISOTHERMAL REACTIVE CRYSTALLISATION PROCESS FOR THE PREPARATION OF A CRYSTALLINE FORM OF PIMODIVIR HYDROCHLORIDE HEMIHYDRATE | October 2020 | November 2022 | Allow | 26 | 0 | 0 | No | No |
| 17043134 | TREATMENT OF TRK-ASSOCIATED CANCERS | September 2020 | August 2023 | Abandon | 34 | 0 | 1 | No | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner TRAN, ERIC works in Art Unit 1629 and has examined 57 patent applications in our dataset. With an allowance rate of 59.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 39 months.
Examiner TRAN, ERIC's allowance rate of 59.6% places them in the 20% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by TRAN, ERIC receive 1.54 office actions before reaching final disposition. This places the examiner in the 28% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by TRAN, ERIC is 39 months. This places the examiner in the 25% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +26.5% benefit to allowance rate for applications examined by TRAN, ERIC. This interview benefit is in the 73% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 38.3% of applications are subsequently allowed. This success rate is in the 88% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 44.4% of cases where such amendments are filed. This entry rate is in the 68% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants file petitions regarding this examiner's actions, 100.0% are granted (fully or in part). This grant rate is in the 89% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 11.8% of allowed cases (in the 90% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.